Developing Bispecific Antibodies for Cancer Treatment

The chapter discusses the creation of bispecific antibodies to recruit killer T-cells for tackling tumors efficiently but with potential risks. It explores the unique challenges in developing effective agonist antibodies, with a focus on discovering low-affinity antibodies for tumor cell killing while minimizing cytokine release. The conversation also covers strategic company structuring for developing new drug candidates against various targets and the importance of creating value across a platform.